Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped down prior to trading on Tuesday. The stock had previously closed at $15.45, but opened at $14.69. Ascentage Pharma Group International shares last traded at $14.6120, with a volume of 3,497 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AAPG shares. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citigroup initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price for the company. William Blair began coverage on shares of Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. reduced their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research report on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $43.90.

Ascentage Pharma Group International Stock Performance

The firm’s 50-day moving average price is $16.17 and its 200-day moving average price is $20.53. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. As a group, sell-side analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.